arrow
S

Susanne Saußele

Heidelberg University
H指数:52
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

慢性髓性白血病患者治疗中断缓解和分子学复发的全面分子特征分析:EURO-SKI生物标志物研究

Leukemia
IF13.4
2026-06-180
OAAI
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase

慢性髓性白血病急变期预后评分系统的开发

Leukemia
IF13.4
2026-02-190
OA
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)

一项比较酪氨酸激酶抑制剂停药后罗培干扰素α-2b与观察随访治疗慢性髓性白血病(ENDURE/CML-IX)的随机Ⅲ期试验

Leukemia
IF13.4
2026-01-120
OAAI
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective

德国慢性髓系白血病患者治疗期望与目标:以患者为中心的视角

Leukemia
IF13.4
2025-12-190
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL

Asciminib在ASCEMBL研究中经过近4年的随访后,在晚期慢性粒细胞白血病慢性期(CML-CP)中仍优于bosutinib。

2025-05-090
OAAI
The Combination of Asciminib with ATP Competing Tyrosine Kinase Inhibitors Might Overcome the Negative Impact of ASXL1 Mutations on Molecular Response in Newly Diagnosed CML Patients

Asciminib与ATP竞争性酪氨酸激酶抑制剂的联合应用可能克服ASXL1突变对初诊CML患者分子反应的负面影响。

BLOOD
IF23.1
2024-11-051
PRE
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
LEUKEMIA
IF13.4
2024-07-102
PRE
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry
LEUKEMIA
IF13.4
2024-03-284
OAAI
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial (Jan, 10.1038/s41375-024-02145-6 , 2024)

更正: 用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果 (1月,10.1038/s41375-024-02145-6,2024)

LEUKEMIA
IF13.4
2024-02-280
OAAI
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial

用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果

LEUKEMIA
IF13.4
2024-01-265
OAAI
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

药物转运体OCTN1基因启动子中的SNP rs460089对伊马替尼治疗的慢性粒细胞白血病患者的无治疗缓解具有预后价值

LEUKEMIA
IF13.4
2023-12-213
OAAI
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study
2023-08-303
OA
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study

第二代酪氨酸激酶抑制剂 (TKI) 治疗后慢性粒细胞白血病 (CML) 慢性期患者中博舒替尼的逐步剂量: 博舒替尼剂量优化 (BODO) 研究的结果

2023-08-189
OAAI
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

在先前用至少两种酪氨酸激酶抑制剂治疗的慢性粒细胞白血病的慢性期中,Asciminib vs bos sutinib: ASCEMBL的长期随访

LEUKEMIA
IF13.4
2023-01-3064
OAAI